Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Genprex Inc. GNPX

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Details Plans to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum

Genprex Inc. (NASDAQ: GNPX), a clinical-stage gene-therapy company, this morning announced that it will be presenting at the upcoming Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum at the Waldorf Astoria Chicago on May 31, 2019. Per the update, Genprex … Continue reading

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Taking Unique Gene Therapy Approach to Cancer Treatment

Genprex (NASDAQ: GNPX) is a clinical-stage, gene-therapy company focused on the advancement of its lead drug candidate, Oncoprex(TM) immunogene therapy. Oncoprex is an investigational therapy for non-small cell lung cancer (“NSCLC”). An article discussing the company reads, “Oncoprex is designed … Continue reading

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Retains Pharmaceutical Branding Agency to Oversee Lead Drug Candidate Naming Process

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) this morning announced that it has retained the services of leading pharmaceutical branding agency, Addison Whitney, representing the next step toward commercialization of its lead drug candidate. Utilizing its 28-year history, Addison Whitney will … Continue reading

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Collaborators Report Positive Preclinical Data in Lung Cancer Treatment Study

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) recently reported that positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody was recorded by its University of Texas MD Anderson Cancer Center collaborators in a lung cancer treatment … Continue reading

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Why Genprex Inc. (NASDAQ: GNPX) Is ‘One to Watch’

Clinical-stage, gene-therapy company Genprex (NASDAQ: GNPX) is focused on the development of potentially life-changing technologies for cancer patients. A recent article discussing GNPX reads, “Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted … Continue reading

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Collaborators Report Positive Preclinical Data at 2019 AACR Annual Meeting

Clinical-stage gene therapy company Genprex Inc. (NASDAQ: GNPX) this morning announced that its collaborators from the University of Texas MD Anderson Cancer Center (“MD Anderson”) detailed positive preclinical data, in a poster presented at the American Association of Cancer Research … Continue reading

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Posts Clinical, Corporate and Financial Update

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Monday provided a clinical, corporate and financial update for the year ended December 31, 2018. Among other highlights, Genprex reached various milestones in 2018 and early 2019 which included completing its initial … Continue reading

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment

Genprex Inc. (NASDAQ: GNPX) is “One to Watch”

Lung cancer is one of the most prevalent and deadly cancers worldwide. Genprex aims to develop cutting-edge gene therapies to improve outcomes, which have not changed significantly in the past 25 years despite radical advances in drug development and novel … Continue reading

Posted in Genprex Inc. GNPX | Leave a comment

MissionIRNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) to Present at Seventh Annual ARM Cell & Gene Therapy Investor Day in New York City

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that it will be presenting at the upcoming ARM Cell & Gene Therapy Investor Day, hosted by the Alliance for Regenerative Medicine, to be held in New York City on … Continue reading

Posted in Genprex Inc. GNPX, MissionIRNewsBreaks | Leave a comment